The global proteomics market size was valued at USD 26,590.5 million in 2021. It is expected to reach USD 76,753.6 million by 2030, growing at a CAGR of 12.5% during the forecast period (2022–2030). Proteomics is the study of both the structure and the functions of proteins. The study of proteomics is more complex than genomics because genomes remain unchanged over time. In contrast, proteomes change depending on the cells and the context in which they are studied due to the increased utility of proteomics in diagnosing diseases and identifying potential new drugs for treating various conditions.
It is anticipated that factors such as a rise in the focus of key players on product development, an increase in the amount spent on R&D for proteomics, an increase in the popularity of personalized medicines, and technological advancements in proteomics will drive the growth of the market. It is anticipated that the development of the market will be hampered by stringent regulatory approvals, the high cost of instruments, and a shortage of qualified researchers.
Get more information on this report Download Sample Report
Growing Demand for Personalized Medicines to Boost Market Progress
In inpatient care, personalized medicine is a multi-faceted approach that improves the ability to diagnose and treat disease and offers the possibility of detecting disease at an earlier stage. This is one of the many benefits of personalized medicine. The expansion of the market for personalized medicine is another important factor contributing to the industry's growth. A form of medical treatment known as personalized medicine is when the patient's specific needs are considered when formulating a treatment plan. It is used extensively in diagnosing and treating cancer in various settings. Emerging in the field of personalized medicine is a new science known as proteomics, which has the potential to make significant contributions of its own. It directly examines cell physiology's molecular machinery, including protein expression, sequence variations and isoforms, post-translational modification, and protein-protein complexes. This gives it an advantage over assays that are based on genomics.
Rising Technological Advancements Associated with Proteomics Components
Recent technological progress in proteomics is anticipated to be a driving force behind the market expansion. These developments have piqued the interest of pharmaceutical and biotechnology companies to venture into proteomics due to the convenience of using the instruments and improved outcomes of the procedures. This interest has been piqued due to the improved results of the procedures. For example, technological advancements such as an increase in the resolution of mass spectrometry help extract useful information from a small amount of sample material.
Similarly, dual mass analyzers such as LC/MS, GC/MS, FT-MS, and MALDI-TOF/TOF can provide additional information regarding the structure of proteins. The innovative MALDI-2 technology has the potential to offer a sensitivity increase of one or two orders of magnitude for a wide variety of small molecules and lipids. In addition, the advancement of methods such as gel electrophoresis and improved liquid chromatography have been of great assistance in separating proteins and identifying them. These technological advancements are anticipated to be the driving force behind the growth of the proteomics market. Because of this, it is expected that the impact of this driver will become more significant throughout the forecast period.
High Costs Associated with the Components of Proteomics to Restrict Market Growth
Due to the need to maintain high-quality standards and comply with guidelines set up by regulatory authorities, the cost of proteomics products is high, hindering the market growth. Only high-quality components, tools, reagents, and other products used in this study will yield accurate results. The mass spectrometers are necessary for proteomics study and cost approximately USD 20,000 each. For developing nations, entering the field of proteomics can be challenging due to the high cost of the necessary instruments and reagents. In addition, the findings of the research and tests conducted do not always turn out as anticipated, and the results might not be considered satisfactory. As a result, the market's growth is hampered by the high cost of the instruments. During the research, there does not appear to be a significant decline in the prices of instruments and reagents. As a result, it is anticipated that the effect of the constraint will be relatively mild in the not-too-distant future.
Detection of Biomarkers to Boost Market Opportunities
Finding and analyzing disease-specific biomarkers in conditions as diverse as cancer, neurological disorders, and cardiovascular diseases can provide a greater understanding of the workings of disease mechanisms. This contributes to a better understanding of the interaction of drugs and their effect on the metabolic pathway, which assists in creating new medicines. Proteomic technologies have a significant amount of untapped potential, particularly in the search for new clinical biomarkers for the early detection and diagnosis of cancer and other diseases, as well as the discovery of new therapeutic targets from bio-specimens that are easily accessible. Differential in-gel electrophoresis, or DIGE, is a relatively new technique that, when combined with liquid chromatography and mass spectrometry (LC/MS), is said to be an effective proteomic method for the molecular characterization of tumor development as well as the detection of tumor-specific biomarkers in esophageal scans cell cancer. As a result, discovering new biomarkers opens up enormous opportunities for the proteomics market.
The global proteomics market has been divided into distinct submarkets based on the component and application
The global proteomics market has been categorized into reagents, instruments, and services based on the component.
The reagents segment was the highest contributor to the market, growing at a CAGR of 11.9% during the forecast period. In the proteomics industry, market participants have made product launch and acquisition two of their primary means of business expansion in recent years. While analyzing the protein structure and characterization, reagents are used as binding materials and precursors of chemical reactions. Because of this, reagents are considered to be an essential component of the proteomics process. As a result, the increased adoption of proteomics in the diagnostic and medical industries has increased the demand for reagents.
The second-largest segment is the instruments segment. Research and development (R & R&D) activities for developing novel instruments used to study encoded proteins' structure and functional roles have seen an unprecedented increase in recent years. This increase has been witnessed. Research into the pathological mechanisms involved in disease progression and identifying drug-targeting sequences benefit from instruments. In recent years, spectroscopy, immunoassays, protein microarrays, and gel-based methods have been used to analyze proteins. For the most part, market participants have settled on product launch as the primary method of business expansion they will pursue in the future to broaden their customer base and solidify their position in the market.
The global proteomics market has been categorized into drug discovery, disease diagnosis, and others based on the application.
The drug discovery segment was the highest contributor to the market, growing at a CAGR of 12.1% during the forecast period. The blood stage of the malaria infection is where purine binding proteins are found, and proteomics is used to find new antimalarial drugs that target these proteins. The advancement of proteomics has enabled researchers to develop personalized medications tailored to each patient's specific needs, resulting in increased therapeutic value with significantly reduced adverse effects. As a result, it is anticipated that advances in proteomics technology will lead to the development of safer, more potent, and more affordable medicines, accelerating the market's expansion.
The field of proteomics makes it easier to locate new disease biomarkers in the body's fluids, cells, and tissues. These biomarkers have clinical uses that include disease diagnosis, patient classification to determine the best course of treatment, disease progression monitoring, and treatment outcome evaluation. For example, proteomics has a significant role in diagnosing tumor metastasis and renal diseases. These factors will ensure that this market segment continues to grow.
The global proteomics market has been studied across North America, Europe, Asia-Pacific, and LAMEA.
Regional Growth Insights Request Sample Pages
North America is the highest revenue contributor growing with a CAGR of 11.1% during the forecast period. Because of the government organization's financial support, proteomics research in North America has significantly improved in recent years. The market experienced significant expansion due to substantial funding from various organizations and increased the number of agreements and collaborations implemented. Additionally, an increase in the amount invested in research and development is anticipated to help facilitate the expansion of the market. On the other hand, it is expected that recent regional economic tensions will harm the growth rate.
Europe is the second-largest contributor to the market and is estimated to reach around USD 20,854.96 million at a CAGR of 11.8% during the forecast period. Because of this, governments and federal departments in three major countries are investing in proteomics research and development. This contributes to the expansion of the market. In addition, the industry is seeing an increase in collaboration between smaller firms and larger suppliers and between firms and academic institutions. Increased demand for personalized medicine, advancements in technology, and bioinformatics in proteomics all contribute to the growth of Europe's proteomics market. Proteomics-specific labs and government funding are also contributing to the market's growth. Regulatory restrictions and high equipment costs hamper proteomics technology development.
Because of financial restraints, the rate of growth of the proteomics industry in the Asia-Pacific region has slowed down in recent years. Proteomics is widely used in the healthcare industry to detect and diagnose diseases due to increased investment in the field by companies based in other countries, even though its market share is relatively low. It is anticipated that the Asia-Pacific proteomics market will experience significant development due to an increase in technological innovations and a substantial increase in funding from both public and private organizations. It is anticipated that increased investment by businesses in research and development activities will propel market expansion.
LAMEA proteomics is expected to grow moderately shortly due to a lack of technological advances. But several businesses are putting their efforts into growing in the area. The market's growth is fueled by increased funding from federal and state governments. There is also expected to be a significant increase in the number of substantial players' collaborations, expansions, and product launches shortly.
The key players in the global Proteomics market included